Holen Sie sich die Stockscreener-App
14.81
4.96%
-0.805
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz - BioSpace
Treatment invented at Nationwide Children’s for kid-killing disease gets FDA approval - The Business Journals
Understanding the Setup: (RARE) and Scalable Risk - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results - Yahoo Finance
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? - Yahoo Finance
Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
RARE Maintained by Evercore ISI Group -- Price Target Raised to $18 - GuruFocus
Is Ultragenyx Stock a Buy With 2 FDA Vouchers Worth a Quarter of Its Market Value? - Investing.com
RARE Maintained by Barclays -- Price Target Raised to $35.00 - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Andelyn Biosciences reaches commercial gene therapy manufacturing milestone with Fayuvi - Manufacturing Chemist
Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is In Focus Now? - Kalkine Media
Ultragenyx wins first-ever FDA approval in Sanfilippo syndrome type A - The Pharma Letter
Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets - AD HOC NEWS
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending - webull.com
FDA approves new gene therapy as first treatment for Sanfilippo A - sanfilipponews.com
Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo - MedCity News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out - ACCESS Newswire
RARE - Finviz
Ultragenyx's $3.95 Million Fayuvi Secures First-Ever FDA Approval for Sanfilippo Syndrome Type A - finance.biggo.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A - BioPharm International
Ultragenyx Turns To Launch Execution After Long Road For Sanfilippo Gene Therapy - insights.citeline.com
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy - yourwyominglink.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00 - MarketBeat
Ultragenyx sets $3.95 million price for rare disease gene therapy - CNBC
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A - PharmExec.com
Ultragenyx secures FDA approval for first treatment of Sanfilippo syndrome type A - AllSci
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest - Benzinga
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $18 to $39 - Moomoo
Ultragenyx Pharmaceutical stock jumps on Fayuvi FDA approval and fresh Cantor Fitzgerald target - AD HOC NEWS
Canaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00 - MarketBeat
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M - BioSpace
FDA approves Ultragenyx gene therapy for rare disorder MPS IIIA - Investing.com
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Cantor Fitzgerald raises Ultragenyx stock price target on gene therapy approval - Investing.com
Abeona Therapeutics (ABEO) Congratulates Ultragenyx on FDA Appro - GuruFocus
FDA approves Ultragenyx gene therapy for rare disorder MPS IIIA By Investing.com - Investing.com Nigeria
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - The Manila Times
A gene therapy for Sanfilippo syndrome gets U.S. approval. Abeona helped develop it. - Stock Titan
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains? - Yahoo Finance
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug - Yahoo Finance
Cantor Fitzgerald maintains Overweight rating on Ultragenyx Pharmaceutical, $39 price target - tradingview.com
Is Ultragenyx Pharmaceutical (RARE) Reasonable After Its FDA Gene Therapy Approval? - simplywall.st
FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A By Investing.com - Investing.com Nigeria
Ultragenyx's $4 million gene therapy wins FDA approval for a rare brain and nervous system disorder - The Business Journals
RARE: FAYUVI receives FDA approval as the first treatment for Sanfilippo syndrome type A - tradingview.com
Ultragenyx gets FDA nod for Sanfilippo gene therapy - FirstWord
RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Ultragenyx Stock Jumps on Landmark FDA Approval - Barron's
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A - NeurologyLive
RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo - GuruFocus
RARE Looks 68.0% Undervalued on GF Value™ After FDA Approval Boo - GuruFocus
FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A - Investing.com
Ultragenyx Shares Rise After FDA Approval for Sanfilippo Syndrome Treatment - marketscreener.com
FDA Approves Ultragenyx’s Sanfilippo Syndrome Gene Therapy - genomeweb.com
Ultragenyx Announces FDA Approval of FAYUVI, the First Treatment for Sanfilippo Syndrome Type A - quiverquant.com
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the - GlobeNewswire
A fatal childhood disease gets its first FDA-approved treatment - Stock Titan
Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome - Seeking Alpha
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 11.5% HigherStill a Buy? - MarketBeat
RARE Looks 70.4% Undervalued on GF Value™ Amid FDA Approval Boos - GuruFocus
US FDA approves Ultragenyx's gene therapy for rare disorder - marketscreener.com
Ultragenyx Pharmaceutical (RARE) Insider Sale: SVP, Chief Accoun - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Connect - ACCESS Newswire
Ultragenyx (NASDAQ: RARE) executive plans $17K stock sale - Stock Titan
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
Technical Reactions to RARE Trends in Macro Strategies - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
0.11%
1.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):